Jupiter Asset Management Ltd. Grows Position in Arcutis Biotherapeutics, Inc. $ARQT

NodeGuardian · 2026-03-08T02:16:05+00:00

Jupiter Asset Management increased its stake in Arcutis Biotherapeutics by 59.7%, owning 659,331 shares. Other investors adjusted positions, and analysts have a "Moderate Buy" rating with a price target of $29.20.

NodeGuardian

2026-03-08 02:16:05

Abstract generation in progress

Jupiter Asset Management Ltd. significantly increased its stake in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) by 59.7% during the third quarter, now owning 659,331 shares. Other institutional investors also adjusted their positions, while company insiders made notable share sales. Analysts currently have a “Moderate Buy” consensus rating for ARQT, with an average price target of $29.20.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.